Evidence map›Paper›PMID 42675181›Full record

ArticleNature biomedical engineering2026

Engineering inflammation-responsive proteins through nitric oxide-caged amino acids.

Wenkang Cai, Junhao Cui, Zhiying Zeng, Zexian Xiang, Yuanzhe Xie, Yeyu Su, Yi Zuo, Yingze Liu, Haoyu Wang, Liying Chang and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Nature biomedical engineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Wenkang Cai *State Key Laboratory of Natural and Biomimetic Drugs, Chemical Biology Center, Institute of Advanced Clinical Medicine, Department of Molecular and Cellular Pharmacology, School of Pharmaceutical Sciences, Peking University, Beijing, China.
Junhao Cui *State Key Laboratory of Natural and Biomimetic Drugs, Chemical Biology Center, Institute of Advanced Clinical Medicine, Department of Molecular and Cellular Pharmacology, School of Pharmaceutical Sciences, Peking University, Beijing, China.
Zhiying Zeng *State Key Laboratory of Natural and Biomimetic Drugs, Chemical Biology Center, Institute of Advanced Clinical Medicine, Department of Molecular and Cellular Pharmacology, School of Pharmaceutical Sciences, Peking University, Beijing, China.
Zexian XiangState Key Laboratory of Natural and Biomimetic Drugs, Chemical Biology Center, Institute of Advanced Clinical Medicine, Department of Molecular and Cellular Pharmacology, School of Pharmaceutical Sciences, Peking University, Beijing, China.
Yuanzhe XieState Key Laboratory of Natural and Biomimetic Drugs, Chemical Biology Center, Institute of Advanced Clinical Medicine, Department of Molecular and Cellular Pharmacology, School of Pharmaceutical Sciences, Peking University, Beijing, China.
Yeyu SuState Key Laboratory of Natural and Biomimetic Drugs, Chemical Biology Center, Institute of Advanced Clinical Medicine, Department of Molecular and Cellular Pharmacology, School of Pharmaceutical Sciences, Peking University, Beijing, China.
Yi ZuoState Key Laboratory of Natural and Biomimetic Drugs, Chemical Biology Center, Institute of Advanced Clinical Medicine, Department of Molecular and Cellular Pharmacology, School of Pharmaceutical Sciences, Peking University, Beijing, China.
Yingze LiuState Key Laboratory of Natural and Biomimetic Drugs, Chemical Biology Center, Institute of Advanced Clinical Medicine, Department of Molecular and Cellular Pharmacology, School of Pharmaceutical Sciences, Peking University, Beijing, China.
Haoyu WangState Key Laboratory of Natural and Biomimetic Drugs, Chemical Biology Center, Institute of Advanced Clinical Medicine, Department of Molecular and Cellular Pharmacology, School of Pharmaceutical Sciences, Peking University, Beijing, China.ORCID http://orcid.org/0000-0001-9721-2891
Liying ChangState Key Laboratory of Natural and Biomimetic Drugs, Chemical Biology Center, Institute of Advanced Clinical Medicine, Department of Molecular and Cellular Pharmacology, School of Pharmaceutical Sciences, Peking University, Beijing, China.
Xue WangState Key Laboratory of Natural and Biomimetic Drugs, Chemical Biology Center, Institute of Advanced Clinical Medicine, Department of Molecular and Cellular Pharmacology, School of Pharmaceutical Sciences, Peking University, Beijing, China.
Jingjing WangState Key Laboratory of Natural and Biomimetic Drugs, Chemical Biology Center, Institute of Advanced Clinical Medicine, Department of Molecular and Cellular Pharmacology, School of Pharmaceutical Sciences, Peking University, Beijing, China.ORCID http://orcid.org/0009-0008-6119-516X
Jun-An MaDepartment of Chemistry, State Key Laboratory Synthetic Biology, Tianjin University, Tianjin, China.
Tao LiuState Key Laboratory of Natural and Biomimetic Drugs, Chemical Biology Center, Institute of Advanced Clinical Medicine, Department of Molecular and Cellular Pharmacology, School of Pharmaceutical Sciences, Peking University, Beijing, China. taoliupku@pku.edu.cn.ORCID http://orcid.org/0000-0001-5347-5892

Funding

National Natural Science Foundation of China (National Science Foundation of China) 22325701National Natural Science Foundation of China (National Science Foundation of China) 92156025National Natural Science Foundation of China (National Science Foundation of China) U22A20332
6 · The paper itself

Abstract

Nitric oxide is upregulated in inflammatory tissues but has not been used to directly control the activity of folded proteins. Here we report a protein engineering strategy that enables selective restoration of protein function in nitric oxide-rich environments. Protein activity is temporarily suppressed by site-specific substitution of a catalytically or structurally essential glutamate residue with a synthetic amino acid whose side chain is chemically masked. Exposure to nitric oxide triggers decaging of this residue, regenerating the native glutamate and restoring protein function. Using this approach, we engineer nitric oxide-responsive variants of antibodies, enzymes, cytokines, bacterial toxins and viral capsids. In mouse models, this strategy enables inflammation-localized protein activation, selective viral gene delivery in inflamed tissues and rapid detection of intestinal inflammation using engineered probiotic biosensors. These results establish nitric oxide-triggered chemical reactivation of proteins as a generalizable method for post-translational control of protein function, with potential applications in inflammation-targeted therapeutics, gene delivery and biosensing.

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.